Compare
Sinovac Biotech Ltd vs Lifevantage Corp vs ANI Pharmaceuticals Inc vs Phibro Animal Health Corp
| Latest fiscal year | Sinovac Biotech Ltd SVA | Lifevantage Corp LFVN | ANI Pharmaceuticals Inc ANIP | Phibro Animal Health Corp PAHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2026-06-30 |
| Revenue | $386.01M | $182.59M | $883.37M | $1.52B |
| Revenue growth (YoY) | +6.8% | -20.1% | +43.8% | +17.1% |
| Gross margin | 67.9% | 77.6% | n/a | 33.8% |
| Operating margin | -127.0% | 3.3% | 12.6% | 12.8% |
| Net margin | -51.5% | 2.8% | 8.9% | 6.6% |
| Net income | -$198.84M | $5.07M | $78.34M | $99.72M |
| EPS (Diluted) | -$0.83 | $0.40 | $3.32 | $2.43 |
| Operating cash flow | -$512.18M | $10.24M | $185.22M | $68.95M |
| Free cash flow | -$561.10M | $6.67M | $171.39M | $9.87M |
| Cash & equivalents | $488.25M | n/a | $285.58M | $61.42M |
| Total assets | $8.54B | $62.11M | $1.44B | $1.50B |
| Total liabilities | $2.15B | $28.52M | $899.65M | $1.12B |
| Shareholders' equity | $6.40B | $33.59M | $540.72M | $385.48M |
| Return on year-end equity | -3.1% | 15.1% | 14.5% | 25.9% |
| Shares outstanding | 71.86M | 12.52M | 22.49M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Sinovac Biotech Ltd | Lifevantage Corp | ANI Pharmaceuticals Inc | Phibro Animal Health Corp |
|---|---|---|---|---|
| Latest | $386.01M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $883.37M Ended 2025-12-31 | $1.52B Ended 2026-06-30 |
| 1 year earlier | $361.37M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $614.38M Ended 2024-12-31 | $1.30B Ended 2025-06-30 |
| 2 years earlier | $470.17M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $486.82M Ended 2023-12-31 | $1.02B Ended 2024-06-30 |
| 3 years earlier | $1.47B Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $316.38M Ended 2022-12-31 | $977.89M Ended 2023-06-30 |
| 4 years earlier | $19.37B Ended 2021-12-31 | $206.36M Ended 2022-06-30 | $216.14M Ended 2021-12-31 | $942.26M Ended 2022-06-30 |